Effects of Autogenic Drainage and Flutter Device in COPD
17. července 2026 aktualizováno: Riphah International University
Comparative Effects of Autogenic Drainage and Flutter Device on Dyspnea, Pulmonary Function Test and Functional Capacity in COPD
COPD is a progressive lung disease that includes emphysema and chronic bronchitis and is a major cause of morbidity and mortality worldwide.
Airway clearance techniques help improve mucus removal, reduce dyspnea, and enhance quality of life in COPD patients.
This study aims to compare the effects of autogenic drainage and flutter device on dyspnea, pulmonary function, and functional capacity in patients with COPD.
A randomized clinical trial will be conducted at Gulab Devi Teaching Hospital using convenient sampling.
Participants will be divided into two groups: Group A will receive autogenic drainage, while Group B will use the flutter device.
Interventions will be performed daily for 20-30 minutes over 6 weeks.
Outcome measures will include dyspnea severity scale, spirometry, and 6-minute walk test.
Data will be analyzed using SPSS with significance set at p < 0.05.
The study may provide evidence for effective, non-invasive, and cost-effective management strategies for COPD patients.
Přehled studie
Postavení
Zatím nenabíráme
Intervence / Léčba
Detailní popis
Chronic obstructive pulmonary disease is progressive damage to lungs with a combination of airway diseases that are emphysema and chronic bronchitis.
COPD is the major cause of chronic mortality and morbidity throughout the world.
It's third leading cause of death in the world.
Non pharmacological intervention Airway clearance techniques plays crucial role in managing COPD and enhancing patients quality of life by removal of bronchial secretions.
Two popular techniques autogenic drainage and flutter are based on the same principle of mobilization and removal of secretions.
These non-invasive techniques aimed at enhancing mucus clearance and reducing dyspnea.
The objective of the study's primary goal is to compare the effect of autogenic drainage and flutter device on the dyspnea, pulmonary function test and functional capacity in the patients with COPD.
The study design will be ramdomized clinical trial.
It will be conducted at Ghulab Devi |Teaching Hospital.
Sample size will be conducted through non- probability convenient sampling as per inclusion criteria.
Participants will be randomly added into two groups.
Group A will receive autogenic drainage intervention and the Group B will receive flutter device intervention.
Both interventions will be practiced daily for 5 days 6 weeks for 20-30 minutes.
Pre and post intervention data will be collected.
Outcome measures include dyspnea severity scale, spirometer and 6-minute walk test.
Data will be analyzed by using SPSS.
Data will be tested for normality distribution.
Paired or Independent t-test will be used to compare variables between the two groups and within the two groups, with significance set at p< 0.05.
This study will provide evidence for the integration of non-invasive, cost effective strategies for the enhancement of PFT's and functional capacity and dyspnea.
Typ studie
Intervenční
Zápis (Odhadovaný)
42
Fáze
- Nelze použít
Kontakty a umístění
Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.
Studijní kontakt
- Jméno: Muhammad Iqbal Tariq Tariq, Phd*
- Telefonní číslo: 333826752
- E-mail: iqbal.tariq@riphah.edu.pk
Studijní záloha kontaktů
- Jméno: Nimra Noor Noor, MS-CPPT
- Telefonní číslo: 03030684869
- E-mail: nimranoor358@gmail.com
Studijní místa
-
-
Punjab Province
-
Lahore, Punjab Province, Pákistán, 40100
- Nimra Noor
-
Kontakt:
- Nimra Noor Noor, MS-CPPT
- Telefonní číslo: 03030684869
- E-mail: nimranoor358@gmail.com
-
-
Kritéria účasti
Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.
Kritéria způsobilosti
Věk způsobilý ke studiu
- Dospělý
Přijímá zdravé dobrovolníky
Ne
Popis
Inclusion Criteria:
- Age group: Middle age adults (40-60 years), medically stable
- Both gender
- Diagnosis based on GOLD criteria ((FEV₁/FVC ratio < 0.70).
- Moderate COPD with no acute exacerbations in the past 4-6 weeks.
- Participants must be able to perform Autogenic drainage and Flutter device physically and mentally.
- Voluntary participation with consent.
Exclusion Criteria:
- Cardic Diseases (Acute MI, Congestive Heart Failure)
- Musculoskeletal Impairements
- Using Non-invasive Ventilation
- Recent lung diseases (Respiratory failure, pneumothorax)
- Hemodynamic instability
- Uncoorperative patients
- Cognitive Impairement scale
- Participants excluded if they did not consent
- Comorbidities affecting exercise tolerance
Studijní plán
Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Autogenic drainage
The participants in this group will be instructed to sit comfortably with the neck slightly extended and clear the upper airways by huffing or blowing the nose.
Autogenic drainage begins with slow diaphragmatic breathing at low lung volumes, followed by a 3-second pause and gentle high-velocity expiration with an open glottis.
As secretions move upward, breathing gradually shifts to medium and high lung volumes until mucus reaches the trachea for expectoration.
The cycle of breathing exercises is repeated for 15-20 minutes while suppressing unnecessary coughing.
|
The patient begins by performing the diaphragmatic breathing at low lung volume inspiration will slow with a pause of three seconds allowing the collateral ventilation, and expiration will done as a sigh with an open glottis and with high velocity as possible but no forced expiration.
During this low lung volume breathing, expiration will encourage to the expiratory reserve volume.
When the patient feel secretions to be moving, the volume of inspiration became deeper and expiration did not go down as far as expiratory reserve volume.
As the secretions moved up the bronchial tree to the large airways then the patient will ask to perform higher lung volume breathing, tidal volume to inspiratory reserve volume range.
This middle to high lung volume breathing continued until the secretions will in the trachea and ready to be expectorated
Ostatní jména:
|
|
Experimentální: Flutter Device (Positive expiratory pressure technique)
The participant in this group will be instructed to sit comfortably while leaning forward with elbows supported and the neck slightly extended to open the airway.
The flutter device is held horizontally with a slight upward tilt and placed in the mouth.
The patient inhales slowly through the nose, holds the breath for 3-5 seconds, and exhales through the flutter device slightly faster than normal.
After 4-8 breaths, a deep inhalation followed by forced expiration through the device helps mobilize secretions.
Breathing control is maintained, followed by coughing or huffing if needed.
The procedure is repeated for 10-15 minutes.
|
The flutter device will hold horizontally and tilted slightly upwards to get maximal oscillatory effect and then it was placed in the mouth.
Inspiration was done through the nose.
A slow breath in, only slightly deeper than normal with a breath hold of 3-5 seconds will followed by breath out through the flutter device at a slightly faster rate than normal.
After 4-8 breaths, a deep breath with a hold' at full inspiration will followed by a force expiration through the flutter device.
This precipitated expectoration and will followed by a pause for breathing control, and then according to the subjects' preference a cough or huff was done
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Dyspnea
Časové okno: Baseline and after 6 weeks of intervention
|
The modified medical research council; (mMRC) Dyspnea Scale is a simple and widely used scale
|
Baseline and after 6 weeks of intervention
|
|
Forced Vital Capacity
Časové okno: Baseline and after 6 weeks of intervention
|
Forced Vital Capacity (FVC) will be measured in liters (L) using spirometry.
FVC represents the maximum volume of air that can be forcefully exhaled after a maximal inspiration.
|
Baseline and after 6 weeks of intervention
|
|
Forced Expiratory Volume in One Second
Časové okno: Baseline and after 6 weeks of intervention
|
Forced Expiratory Volume in One Second (FEV₁) will be measured in liters (L) using spirometry.
FEV₁ represents the volume of air exhaled during the first second of a forced expiratory maneuver.
|
Baseline and after 6 weeks of intervention
|
|
FEV₁/FVC ratio
Časové okno: Baseline and after 6 weeks of intervention
|
The FEV₁/FVC ratio will be expressed as a percentage (%) and calculated from spirometric measurements to assess the degree of airflow limitation.
|
Baseline and after 6 weeks of intervention
|
|
Peak Expiratory Flow
Časové okno: Baseline and after 6 weeks of intervention
|
Peak Expiratory Flow (PEF) will be measured in liters per minute (L/min) and represents the maximum expiratory flow achieved during forced expiration.
|
Baseline and after 6 weeks of intervention
|
Spolupracovníci a vyšetřovatelé
Zde najdete lidi a organizace zapojené do této studie.
Sponzor
Vyšetřovatelé
- Vrchní vyšetřovatel: Arjumand Bano, MS, Riphah International University
Termíny studijních záznamů
Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.
Hlavní termíny studia
Začátek studia (Odhadovaný)
1. června 2026
Primární dokončení (Odhadovaný)
1. srpna 2026
Dokončení studie (Odhadovaný)
1. srpna 2026
Termíny zápisu do studia
První předloženo
8. června 2026
První předloženo, které splnilo kritéria kontroly kvality
17. července 2026
První zveřejněno (Aktuální)
20. července 2026
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
20. července 2026
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
17. července 2026
Naposledy ověřeno
1. července 2026
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- REC/RCR & AHS/25/0309
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
NE
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Ne
Studuje produkt zařízení regulovaný americkým úřadem FDA
Ne
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .